Prof Collen, a world renowned scientist, has played an instrumental role in ThromboGenics’ development and subsequent success since he founded the Company in 1991.
During his tenure as CEO of ThromboGenics, the company started its research on JETREA (ocriplasmin) and advanced it through its early clinical development for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT). He was appointed ThromboGenics’ Chairman at the founding of the company.
Before the successful development of JETREA, Prof Collen led the research and development of tissue plasminogen activator (tPA), a key product for Genentech in the late 1980s and 1990s.
Prof Collen, a world renowned scientist, has played an instrumental role in ThromboGenics’ development and subsequent success since he founded the Company in 1991.
During his tenure as CEO of ThromboGenics, the company started its research on JETREA (ocriplasmin) and advanced it through its early clinical development for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT). He was appointed ThromboGenics’ Chairman at the founding of the company.
Before the successful development of JETREA, Prof Collen led the research and development of tissue plasminogen activator (tPA), a key product for Genentech in the late 1980s and 1990s.
Prof Collen has won numerous awards, including two recent lifetime achievement awards as recognition of his excellent services to the global industry. He has co-authored more than 650 scientific publications, and has co-invented over 20 issued patents and patent applications. In 1998 he set up Life Sciences Research Partners, which invests in emerging life sciences companies and promotes scientific research through grants, scholarships and related activities.
Prof Collen holds a M.D. degree (1968) and Ph.D. degree in Chemistry (1974) from Katholieke Universiteit Leuven, Belgium.
Staf Van Reet, currently a member of the ThromboGenics Board and a seasoned biopharma veteran, has been appointed Chairman of ThromboGenics.
Dr. Van Reet was previously Head of R&D at Janssen Pharmaceuticals, and was co-founder of Movetis N.V. and Chairman of its Board of Directors until November 2010, when the company was acquired by Shire S.a.r.l. ■